Stablepoint Partners LLC Decreases Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Stablepoint Partners LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,798 shares of the medical research company’s stock after selling 135 shares during the period. Stablepoint Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,976,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in TMO. Novare Capital Management LLC raised its position in Thermo Fisher Scientific by 2.1% in the fourth quarter. Novare Capital Management LLC now owns 23,515 shares of the medical research company’s stock valued at $12,233,000 after purchasing an additional 490 shares during the period. Clarendon Private LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $440,000. Regency Capital Management Inc. DE acquired a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $3,701,000. Archford Capital Strategies LLC lifted its stake in Thermo Fisher Scientific by 2.0% during the fourth quarter. Archford Capital Strategies LLC now owns 4,101 shares of the medical research company’s stock worth $2,134,000 after purchasing an additional 80 shares during the last quarter. Finally, AlphaMark Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 3.2% in the 4th quarter. AlphaMark Advisors LLC now owns 2,308 shares of the medical research company’s stock worth $1,201,000 after buying an additional 72 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,850 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $557.89, for a total value of $3,263,656.50. Following the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,611,804.88. This represents a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 44,850 shares of company stock valued at $24,666,097 over the last three months. 0.34% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TMO. Redburn Atlantic assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They set a “buy” rating and a $680.00 price objective on the stock. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Robert W. Baird cut their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Barclays dropped their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Finally, Morgan Stanley decreased their target price on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating for the company in a research report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $648.95.

Thermo Fisher Scientific Trading Up 0.1 %

Thermo Fisher Scientific stock opened at $575.21 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The firm’s 50 day moving average price is $533.60 and its two-hundred day moving average price is $569.32. The firm has a market cap of $220.02 billion, a price-to-earnings ratio of 36.06, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. During the same period last year, the company posted $5.69 earnings per share. The business’s revenue for the quarter was up .2% on a year-over-year basis. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its board has approved a stock buyback program on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a dividend of $0.39 per share. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.